Circulating androgen receptor gene amplification and resistance to ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.

ABSTRACT:

Background

In a Phase 2 clinical trial, we aimed to determine the lutetium-177 [¹⁷⁷Lu]-PSMA-617 activity and the clinical utility of levels of plasma androgen receptor (AR) gene in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

Methods

We determined AR copy number in pretreatment plasma samples. We used logistic regression to estimate the odds ratio (OR) and 95% confidence intervals (95% CIs) in order to evaluate the independent relevance of AR status and to evaluate patients with early progressive disease (PD) defined as treatment interruption occurring within 4 months after the start of ¹⁷⁷Lu-PSMA-617.

Results

Twelve of the 15 (80%) with AR gene gain and 5 of the 25 (20%) patients with no gain of AR ha

SUBMITTER: De Giorgi U 

PROVIDER: S-EPMC8548293 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature